Ardelyx, Inc.

ARDX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001437402

A

strongest fifth of 305 graded peers in healthcare

rank 47 of 305; percentile 15.1; sampling error 2.8 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	B/C percentile 42.2
Solvency	C percentile 45.7
Growth and financing	A/B percentile 18.0
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $501.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	8 of 13
Graded from	filings received through Feb 19, 2026 271 days before the rescan; latest periodic filing 10-Q received Nov 3, 2026
Last close	$3.08 2026-11-16; market equity $773.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

We are a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. We currently market two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor that was discovered and developed by Ardelyx. NHE3 is an antiporter expressed on the apical surface of the small and large intestines. Tenapanor is a minimally absorbed, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA®, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 42.2						
Gross profitability	73.3%	32.8%		11.3	346	2025-12-31
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(4.1%)	(6.7%)		65.4	756	2025-12-31
Gross margin stability, five years	2.8 pts	2.8 pts		50.0	237	2025-12-31
Solvency, sleeve percentile 45.7						
Altman Z double-prime	(2.34)	0.31		47.9	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(3.61x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	4.31x	2.68x		43.6	781	2025-12-31
Growth and financing, sleeve percentile 18.0						
Revenue growth, three-year compound	98.4%	9.6%		5.8	400	2025-12-31
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	38.2%	3.2%		11.3	663	2025-12-31
Net share issuance, one year	2.9%	1.6%		36.9	624	2026-02-12

Among 305 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
42	Utah Medical Products Inc. (UTMD)	13.5	A	fortress balance sheet
43	Procept BioRobotics Corp. (PRCT)	13.8	A	fortress balance sheet
44	Resmed Inc. (RMD)	14.1	A	fortress balance sheet
45	PRO DEX Inc. (PDEX)	14.5	A	
46	Insulet Corp. (PODD)	14.8	A	
47	Ardelyx, Inc. (ARDX)	15.1	A	
48	Lantheus Holdings, Inc. (LNTH)	15.5	A	
49	Harrow, Inc. (HROW)	15.8	A	late filer
50	TG Therapeutics, Inc. (TGTX)	16.1	A	
51	Natures Sunshine Products Inc. (NATR)	16.4	A	fortress balance sheet
52	Alnylam Pharmaceuticals, Inc. (ALNY)	16.8	A	

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(43.6%)	(1.7%)	19
Distance from 52-week high	(61.6%)	(31.5%)	20
EBIT to enterprise value	(4.2%)	0.5%	39
Free cash flow yield	(5.7%)	0.5%	33
Book value to price	0.21	0.28	42

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Sales to price	0.53	0.36	62
Composite equity issuance, five years	93.5%	13.2%	82
Relative strength against the sector, log excess return	(0.74)	(0.19)	19
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 2 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$46.3M
Operating cash flow, four quarters	-$15.5M
Months of runway	35.8
Days since last periodic filing	14 (10-Q received Nov 3, 2026)
Median daily dollar volume, 63 sessions	$14.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$407.3M	2025-12-31	2026-02-19	10-K	26-000013
2	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$39.5M	2025-12-31	2026-02-19	10-K	26-000013
3	assets	us-gaap:Assets	$501.6M	2025-12-31	2026-02-19	10-K	26-000013
4	operating income	us-gaap:OperatingIncomeLoss	-$41.0M	2025-12-31	2026-02-19	10-K	26-000013
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$60.6M	2025-12-31	2026-02-19	10-K	26-000013
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$969,000	2025-12-31	2026-02-19	10-K	26-000013
7	total debt	us-gaap:LongTermDebt	$202.8M	2025-12-31	2026-02-19	10-K	26-000013
8	book equity	us-gaap:StockholdersEquity	$166.9M	2025-12-31	2026-02-19	10-K	26-000013
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$68.0M	2025-12-31	2026-02-19	10-K	26-000013
10	total debt	us-gaap:LongTermDebt	$150.9M	2024-12-31	2026-02-19	10-K	26-000013
11	book equity	us-gaap:StockholdersEquity	$173.3M	2024-12-31	2026-02-19	10-K	26-000013
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$64.9M	2024-12-31	2026-02-19	10-K	26-000013
13	net income	us-gaap:NetIncomeLoss	-$61.6M	2025-12-31	2026-02-19	10-K	26-000013
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$42.5M	2025-12-31	2026-02-19	10-K	26-000013
15	assets	us-gaap:Assets	$435.8M	2024-12-31	2026-02-19	10-K	26-000013
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$333.6M	2024-12-31	2026-02-19	10-K	26-000013
17	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$50.6M	2024-12-31	2026-02-19	10-K	26-000013
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$124.5M	2023-12-31	2026-02-19	10-K	26-000013
19	cost of revenue	us-gaap:CostOfGoodsAndServicesSold	$17.8M	2023-12-31	2026-02-19	10-K	26-000013
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$52.2M	2022-12-31	2025-02-20	10-K	25-006653
21	cost of revenue	us-gaap:CostOfRevenue	$4.1M	2022-12-31	2023-03-02	10-K	23-006041
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$10.1M	2021-12-31	2024-02-22	10-K	24-006393
23	cost of revenue	us-gaap:CostOfRevenue	$1.0M	2021-12-31	2023-03-02	10-K	23-006041
24	current assets	us-gaap:AssetsCurrent	$382.3M	2025-12-31	2026-02-19	10-K	26-000013
25	current liabilities	us-gaap:LiabilitiesCurrent	$88.6M	2025-12-31	2026-02-19	10-K	26-000013
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$946.9M	2025-12-31	2026-02-19	10-K	26-000013

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	liabilities	us-gaap:Liabilities	$334.7M	2025-12-31	2026-02-19	10-K	26-000013
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$3.1M	2025-12-31	2026-02-19	10-K	26-000013
29	operating income	us-gaap:OperatingIncomeLoss	-$63.3M	2023-12-31	2026-02-19	10-K	26-000013
30	interest expense	us-gaap:InterestExpense	$5.0M	2023-12-31	2024-02-22	10-K	24-006393
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.5M	2025-12-31	2026-02-19	10-K	26-000013
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$44.8M	2024-12-31	2026-02-19	10-K	26-000013
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.0M	2024-12-31	2026-02-19	10-K	26-000013
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$89.7M	2023-12-31	2026-02-19	10-K	26-000013
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$344,000	2023-12-31	2026-02-19	10-K	26-000013
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$70.0M	2022-12-31	2025-02-20	10-K	25-006653
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$55,000	2022-12-31	2025-02-20	10-K	25-006653
38	current assets	us-gaap:AssetsCurrent	$356.5M	2024-12-31	2026-02-19	10-K	26-000013
39	current liabilities	us-gaap:LiabilitiesCurrent	$77.8M	2024-12-31	2026-02-19	10-K	26-000013
40	assets	us-gaap:Assets	$297.6M	2023-12-31	2025-02-20	10-K	25-006653
41	assets	us-gaap:Assets	$190.1M	2022-12-31	2024-02-22	10-K	24-006393
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	245,247,427	2026-02-12	2026-02-19	10-K	26-000013
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	238,356,222	2025-02-14	2025-02-20	10-K	25-006653

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.